US2016319015A1PendingUtilityA1

Leptin in immune modulation

58
Assignee: ENZO THERAPEUTICS INC C/O ENZO BIOCHEM INCPriority: Oct 8, 2004Filed: Jul 7, 2016Published: Nov 3, 2016
Est. expiryOct 8, 2024(expired)· nominal 20-yr term from priority
Inventors:Yaron IlanEran Elinav
A61P 37/02A61P 35/02A61P 3/10A61P 35/00A61P 37/04A61P 37/00A61P 29/00A61P 15/08A61P 1/16A61P 1/00A61P 19/02A61K 38/02A61K 38/1796A61K 38/22C07K 2317/30A61K 2039/505A61K 38/16C07K 2317/76A61K 38/2264C07K 16/26C07K 16/2869A61P 17/06A61K 39/3955A61N 5/10C07K 14/5759A61K 45/06C07K 14/72
58
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to methods for treating inflammatory bowel disease and other indications by inhibiting leptin activity.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method for treating inflammatory bowel disease, comprising:
 administering to a human patient having Crohn's disease or ulcerative colitis, a therapeutically effective amount of a protein that binds to and antagonizes leptin,   wherein the protein is selected from the group consisting of an antibody, an antibody fragment and a soluble receptor for leptin.   
     
     
         2 . The method of  claim 1 , wherein the human patient has Crohn's disease. 
     
     
         3 . The method of  claim 2 , wherein the protein is an antibody or antibody fragment that binds to and antagonizes leptin. 
     
     
         4 . The method of  claim 3 , wherein the protein is a monoclonal antibody or a fragment of a monoclonal antibody. 
     
     
         5 . The method of  claim 2 , wherein the protein is a soluble receptor for leptin. 
     
     
         6 . The method of  claim 1 , wherein the human patient has ulcerative colitis. 
     
     
         7 . The method of  claim 6 , wherein the protein is an antibody or antibody fragment that binds to and antagonizes leptin. 
     
     
         8 . The method of  claim 7 , wherein the protein is a monoclonal antibody or a fragment of a monoclonal antibody. 
     
     
         9 . The method of  claim 6 , wherein the protein is a soluble receptor for leptin. 
     
     
         10 . A method for treating inflammatory bowel disease, comprising:
 administering to a human patient having Crohn's disease or ulcerative colitis, a therapeutically effective amount of a protein that binds to and antagonizes a leptin receptor,   wherein the protein is selected from the group consisting of an antibody and an antibody fragment.   
     
     
         11 . The method of  claim 10 , wherein the human patient has Crohn's disease. 
     
     
         12 . The method of  claim 11 , wherein the protein is an antibody or antibody fragment that binds to and antagonizes the leptin receptor. 
     
     
         13 . The method of  claim 12 , wherein the protein is a monoclonal antibody or a fragment of a monoclonal antibody. 
     
     
         14 . The method of  claim 10 , wherein the human patient has ulcerative colitis. 
     
     
         15 . The method of  claim 14 , wherein the protein is an antibody or antibody fragment that binds to and antagonizes leptin. 
     
     
         16 . The method of  claim 15 , wherein the protein is a monoclonal antibody or a fragment of a monoclonal antibody.

Join the waitlist — get patent alerts

Track US2016319015A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.